Comparative Evaluation of Insulin Therapy and Oral Antidiabetic Drugs in Type 2 Diabetes Mellitus: Glycemic, Metabolic, and Cardiovascular Perspectives
SN Comprehensive Clinical Medicine · 28.10.2026 · 8 (1)
DOI: 10.1007/s42399-026-02845-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift SN Comprehensive Clinical Medicine, online erschienen am 28.10.2026. Verfasst von Pawan Kumar Goswami und 1 weiteren Autor:innen. Die Arbeit nennt 112 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Insulin resistance and a slow decrease of β-cell activity cause persistent hyperglycemia in type 2 diabetes mellitus (T2DM), a chronic and progressive metabolic disease. While SGLT2 inhibitors, DPP-4 inhibitors, and GLP-1 receptor agonists are among the more recent oral antidiabetic medications (OADs) that have expanded the options for managing diabetes, insulin has always been a crucial therapy option, especially for patients with severe illness. The comparative functions of insulin and OADs are examined in this narrative review, with a focus on glycaemic control, hypoglycemia, changes in body weight, cardiovascular effects, and treatment compliance. Using PubMed, Scopus, Web of Science, and Google Scholar, pertinent literature from the last ten years was examined with a focus on clinical research, randomised controlled trials, and pertinent reviews. Insulin often offers robust and consistent glycaemic control, particularly in advanced type 2 diabetes; nevertheless, hypoglycemia, weight gain, and challenges with long-term adherence may accompany its usage. In contrast, a number of more recent OADs, especially SGLT2 inhibitors and GLP-1 receptor agonists, provide advantages beyond glucose lowering, such as weight loss and protection for the heart and kidneys. However, oral treatment alone may eventually become less effective due to growing β-cell failure, necessitating the initiation or intensification of insulin for certain patients. In general, glycaemic needs, comorbidities, safety, patient preferences, adherence, and disease progression should all be taken into consideration when making treatment decisions. Therefore, more effective long-term management of T2DM can be achieved while lowering complications and enhancing patient quality of life with a timely and balanced mix of OADs and insulin. Graphical Abstract Comparative assessment of insulin and oral antidiabetic drugs focusing on glycemic control, hypoglycemia risk, safety, cost-effectiveness, and long-term clinical outcomes.
Zitieren
APA
Goswami, P. K., & Patel, A. K. (2026). Comparative Evaluation of Insulin Therapy and Oral Antidiabetic Drugs in Type 2 Diabetes Mellitus: Glycemic, Metabolic, and Cardiovascular Perspectives. SN Comprehensive Clinical Medicine, 8(1). https://doi.org/10.1007/s42399-026-02845-3
Vancouver
Goswami PK, Patel AK. Comparative Evaluation of Insulin Therapy and Oral Antidiabetic Drugs in Type 2 Diabetes Mellitus: Glycemic, Metabolic, and Cardiovascular Perspectives. SN Comprehensive Clinical Medicine. 2026;8(1). doi:10.1007/s42399-026-02845-3
BibTeX
@article{Goswami2026,
author = {Goswami, Pawan Kumar and Patel, Arvind Kumar},
title = {Comparative Evaluation of Insulin Therapy and Oral Antidiabetic Drugs in Type 2 Diabetes Mellitus: Glycemic, Metabolic, and Cardiovascular Perspectives},
journal = {SN Comprehensive Clinical Medicine},
year = {2026},
volume = {8},
number = {1},
doi = {10.1007/s42399-026-02845-3}
}
EUVIMED